WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) 3-Year Revenue Growth Rate : 52.00% (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) 3-Year Revenue Growth Rate?

WuXi Biologics (Cayman)'s Revenue per Share for the six months ended in Jun. 2023 was $0.55.

During the past 12 months, WuXi Biologics (Cayman)'s average Revenue per Share Growth Rate was 18.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 52.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 50.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of WuXi Biologics (Cayman) was 65.30% per year. The lowest was 42.10% per year. And the median was 53.35% per year.

Competitive Comparison of WuXi Biologics (Cayman)'s 3-Year Revenue Growth Rate

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman)'s 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s 3-Year Revenue Growth Rate falls into.

WuXi Biologics (Cayman) 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

WuXi Biologics (Cayman) (OTCPK:WXXWY) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

WuXi Biologics (Cayman) 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

WXIBF:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.